113 related articles for article (PubMed ID: 35751096)
1. An in vitro redox adaptation model for metastatic prostate cancer: Establishing, characterizing and Cabazitaxel response evaluating.
Eryilmaz IE; Egeli U; Cecener G
Clin Exp Pharmacol Physiol; 2022 Oct; 49(10):1094-1104. PubMed ID: 35751096
[TBL] [Abstract][Full Text] [Related]
2. Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypes.
Eryilmaz IE; Egeli U; Cecener G
Cancer Biol Ther; 2024 Dec; 25(1):2329368. PubMed ID: 38485703
[TBL] [Abstract][Full Text] [Related]
3. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.
Onstenk W; Sieuwerts AM; Kraan J; Van M; Nieuweboer AJ; Mathijssen RH; Hamberg P; Meulenbeld HJ; De Laere B; Dirix LY; van Soest RJ; Lolkema MP; Martens JW; van Weerden WM; Jenster GW; Foekens JA; de Wit R; Sleijfer S
Eur Urol; 2015 Dec; 68(6):939-45. PubMed ID: 26188394
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
6. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
van Soest RJ; Nieuweboer AJ; de Morrée ES; Chitu D; Bergman AM; Goey SH; Bos MM; van der Meer N; Hamberg P; de Wit R; Mathijssen RH;
Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?
Oudard S; Angelergues A
Nat Rev Urol; 2014 Jul; 11(7):370-2. PubMed ID: 24960604
[TBL] [Abstract][Full Text] [Related]
8. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
9. Association between the anticancer efficacy of cabazitaxel and toll-like receptor 4 mediating signaling pathways in metastatic castration-resistant prostate cancer cells.
Guney Eskiler G; Ozkan AD; Eryilmaz IE; Egeli U; Cecener G
Hum Exp Toxicol; 2021 Jul; 40(7):1122-1129. PubMed ID: 33380212
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
11. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.
Kanao K; Ito T; Takahara K; Ando R; Yasui T; Shiroki R; Miyake H; Sumitomo M
Jpn J Clin Oncol; 2019 Dec; 49(11):1043-1048. PubMed ID: 31369101
[TBL] [Abstract][Full Text] [Related]
13. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program.
Parente P; Ng S; Parnis F; Guminski A; Gurney H
Asia Pac J Clin Oncol; 2017 Dec; 13(6):391-399. PubMed ID: 28488360
[TBL] [Abstract][Full Text] [Related]
15. PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.
Hammerer P; Al-Batran SE; Windemuth-Kieselbach C; Keller M; Hofheinz RD
World J Urol; 2018 Mar; 36(3):375-381. PubMed ID: 29305637
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology).
Süner A; Aydın D; Hacıoğlu MB; Doğu GG; İmamoğlu GI; Menekşe S; Pilancı KN; Yazıcı ÖK; Koca D; Karaağaç M; Akyol M; Akman T; Ergen S; Avcı N; Kaçan T; Bozkurt O; Kefeli U; Urakçı Z; Araz M; Arpacı E; Harputlu H; Sevinç A
Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1238-43. PubMed ID: 27097941
[TBL] [Abstract][Full Text] [Related]
17. Targeting Nrf2-antioxidant signalling reverses acquired cabazitaxel resistance in prostate cancer cells.
Endo S; Kawai M; Hoshi M; Segawa J; Fujita M; Matsukawa T; Fujimoto N; Matsunaga T; Ikari A
J Biochem; 2021 Sep; 170(1):89-96. PubMed ID: 33729485
[TBL] [Abstract][Full Text] [Related]
18. Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.
Bando Y; Hinata N; Terakawa T; Furukawa J; Harada KI; Nakano Y; Fujisawa M
Med Oncol; 2017 Aug; 34(9):163. PubMed ID: 28819719
[TBL] [Abstract][Full Text] [Related]
19. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
[TBL] [Abstract][Full Text] [Related]
20. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]